Kowa boosts US presence with ProEthic buy
This article was originally published in Scrip
Executive Summary
Kowa has acquired ProEthic Pharmaceuticals in a move which will jump-start the Japanese firm's commercial presence and independent marketing capability in the US ahead of the planned 2010 launch in this key market of its high cholesterol drug pitavastatin.